An Open‐label Phase 1 Dose‐escalation Clinical Trial of a Single Intravenous Administration of Gemcitabine in Dogs with Advanced Solid Tumors

BACKGROUND: A broad range of gemcitabine dosages have been used in dogs. HYPOTHESIS/OBJECTIVES: To determine maximally tolerated dose (MTD), dose‐limiting toxicity (DLT), and preliminary antitumor activity of intravenous administration of gemcitabine in dogs with advanced solid tumors. ANIMALS: Twen...

Descripción completa

Detalles Bibliográficos
Autores principales: Marconato, L., Finotello, R., Bonfanti, U., Dacasto, M., Beatrice, L., Pizzoni, S., Leone, V.F., Balestra, G., Furlanello, T., Rohrer Bley, C., Aresu, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Standard Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895507/
https://www.ncbi.nlm.nih.gov/pubmed/25818216
http://dx.doi.org/10.1111/jvim.12557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895507/
https://www.ncbi.nlm.nih.gov/pubmed/25818216
http://dx.doi.org/10.1111/jvim.12557

Ejemplares similares